Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae

Vicki L. Collins, Dror Marchaim, Jason M. Pogue, Judy Moshos, Suchitha Bheemreddy, Bharath Sunkara, Alex Shallal, Neelu Chugh, Sara Eiseler, Pragati Bhargava, Christopher Blunden, Paul R. Lephart, Babar Irfan Memon, Kayoko Hayakawa, Odaliz Abreu-Lanfranco, Teena Chopra, Luisa Munoz-Price, Yehuda Carmeli, Keith S. Kaye

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).

Original languageEnglish
Pages (from-to)2173-2177
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Enterobacteriaceae
Carbapenems
meropenem
Infection
Acinetobacter baumannii
Imipenem
Pseudomonas aeruginosa
Therapeutics
Mortality
ertapenem

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. / Collins, Vicki L.; Marchaim, Dror; Pogue, Jason M.; Moshos, Judy; Bheemreddy, Suchitha; Sunkara, Bharath; Shallal, Alex; Chugh, Neelu; Eiseler, Sara; Bhargava, Pragati; Blunden, Christopher; Lephart, Paul R.; Memon, Babar Irfan; Hayakawa, Kayoko; Abreu-Lanfranco, Odaliz; Chopra, Teena; Munoz-Price, Luisa; Carmeli, Yehuda; Kaye, Keith S.

In: Antimicrobial Agents and Chemotherapy, Vol. 56, No. 4, 01.04.2012, p. 2173-2177.

Research output: Contribution to journalArticle

Collins, VL, Marchaim, D, Pogue, JM, Moshos, J, Bheemreddy, S, Sunkara, B, Shallal, A, Chugh, N, Eiseler, S, Bhargava, P, Blunden, C, Lephart, PR, Memon, BI, Hayakawa, K, Abreu-Lanfranco, O, Chopra, T, Munoz-Price, L, Carmeli, Y & Kaye, KS 2012, 'Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae', Antimicrobial Agents and Chemotherapy, vol. 56, no. 4, pp. 2173-2177. https://doi.org/10.1128/AAC.05913-11
Collins, Vicki L. ; Marchaim, Dror ; Pogue, Jason M. ; Moshos, Judy ; Bheemreddy, Suchitha ; Sunkara, Bharath ; Shallal, Alex ; Chugh, Neelu ; Eiseler, Sara ; Bhargava, Pragati ; Blunden, Christopher ; Lephart, Paul R. ; Memon, Babar Irfan ; Hayakawa, Kayoko ; Abreu-Lanfranco, Odaliz ; Chopra, Teena ; Munoz-Price, Luisa ; Carmeli, Yehuda ; Kaye, Keith S. / Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. In: Antimicrobial Agents and Chemotherapy. 2012 ; Vol. 56, No. 4. pp. 2173-2177.
@article{bb25ce785e3c44bb97d574174d70d846,
title = "Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae",
abstract = "Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6{\%} and 18{\%}, respectively; P = 0.18).",
author = "Collins, {Vicki L.} and Dror Marchaim and Pogue, {Jason M.} and Judy Moshos and Suchitha Bheemreddy and Bharath Sunkara and Alex Shallal and Neelu Chugh and Sara Eiseler and Pragati Bhargava and Christopher Blunden and Lephart, {Paul R.} and Memon, {Babar Irfan} and Kayoko Hayakawa and Odaliz Abreu-Lanfranco and Teena Chopra and Luisa Munoz-Price and Yehuda Carmeli and Kaye, {Keith S.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1128/AAC.05913-11",
language = "English",
volume = "56",
pages = "2173--2177",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae

AU - Collins, Vicki L.

AU - Marchaim, Dror

AU - Pogue, Jason M.

AU - Moshos, Judy

AU - Bheemreddy, Suchitha

AU - Sunkara, Bharath

AU - Shallal, Alex

AU - Chugh, Neelu

AU - Eiseler, Sara

AU - Bhargava, Pragati

AU - Blunden, Christopher

AU - Lephart, Paul R.

AU - Memon, Babar Irfan

AU - Hayakawa, Kayoko

AU - Abreu-Lanfranco, Odaliz

AU - Chopra, Teena

AU - Munoz-Price, Luisa

AU - Carmeli, Yehuda

AU - Kaye, Keith S.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).

AB - Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P = 0.18).

UR - http://www.scopus.com/inward/record.url?scp=84858627256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858627256&partnerID=8YFLogxK

U2 - 10.1128/AAC.05913-11

DO - 10.1128/AAC.05913-11

M3 - Article

C2 - 22290982

AN - SCOPUS:84858627256

VL - 56

SP - 2173

EP - 2177

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -